Fosamax® Side Effects
Osteonecrosis of the JawFosamax® has been linked to a brutal bone disease that causes a jaw disorder known as osteonecrosis of the jaw (ONJ), often referred to as Dead Jaw Syndrome. Osteonecrosis of the jaw is a serious disorder that causes severe pain, swelling, infection and exposure of the jaw bone. It is defined as an exposed bone in the mouth that does not heal after remedy of over 6 to 8 weeks. Although Merck claims that the presence of Osteonecrosis among Fosamax® users is “negligible,” many dental professionals are acknowledging that it is a recurring problem among users of the drug.
Symptoms of ONJ are:
- Gum infections
- Jaw discomfort and pain
- Jaw numbness
- Falling or loosened teeth
Fosamax® Femur FracturesThe FDA has included a warning label on bisphosphonate drugs such as Fosamax® indicating the risk a bone breaks or stress fractures to the thigh. These fractures develope as a result of a reduction of any tissue continuity within the bone. Therefore, even “low energy” or mild trauma will result in serious injuries to the bone. Consequently, users are experiencing leg fractures from unusual circumstances, such as climbing stairs, or even walking even though the femur bone is one of the sturdiest and biggest bones in the body. They are known to be both unprompted and out of the ordinary.
Gastrointestinal Problems Associated with Fosamax®Individual use of Fosamax® has been associated with many gastrointestinal tract abnormalities such as:
- Abdominal cramping
- Esophageal problems including esophagitis, esophageal ulcers and esophageal erosions. Recently it has been linked to esophageal cancer
Fosamax® FDA Recalls and WarningsAlmost immediately after Fosamax® was introduced into the market, the FDA began criticism of the product. Only a year after being placed on the market, the FDA sent Merck a warning letter indicating that they were overstating the benefits of the drug while failing to account for the risks in their marketing materials. In 2004, FDA research concluded that long-term use of Fosamax® is directly related to osteonecrosis of the jaw. In 2008, the FDA issued a warning that bisphosphonate drugs such as Fosamax® cause sever bone, muscle and joint pain. On October 13, 2010, the FDA required that Fosamax® contain a black box warning that use of the medication, even as prescribed may lead to femur breakage. Only a year later, another warning was added to indicate that the duration of the efficacy of Fosamax® is undetermined.
Fosamax® Lawsuits and ClaimsIn light of the FDA’s research, as well as some severe complications associated with Fosamax®, several civil trials have commenced against its parent company, Merck & Co. Although Merck has been forced to somewhat recognize their fault, they still vigorously maintain their innocence in trials. In 2004, thousands of clients filed a multidistrict litigation (MDL) lawsuit against Merck in New York and New Jersey. A MDL is a federal procedure of combining complex civil cases with similar fact patterns. Downtown L.A. Law Group will fight Merck & Company for your Fosamax® claim. We urge you that no matter where you turn for representation, that you avoid any form of communication with Merck, its representative or any party affiliated with the drug. We offer victims of Fosamax® a free 60-minute consultation to discuss their case, fears and concerns. Please call us today if you have been effected at (855)385-2529.
|Generic Name:||Sodium Alenronate|
|Manufacturer:||Merck & Company|
|Uses:||Osteoporosis, Bone Loss, Paget’s Disease|
|Side Effects:||Osteonecrosis, Femur Fractures, Esophegeal Disorders, Bone Pain|